Hostname: page-component-7b7567c8c-slfcl Total loading time: 0 Render date: 2026-11-19T11:35:14.491Z Has data issue: false hasContentIssue false

Hydroxyapatite-dextran methacrylate core/shell hybrid nanocarriers for combinatorial drug therapy

Published online by Cambridge University Press:  13 August 2020

S. Ram Prasad
Affiliation:
Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai600 036, Tamil Nadu, IndiaMedical Materials Laboratory, Department of Metallurgical and Materials Engineering, Indian Institute of Technology Madras, Chennai600 036, Tamil Nadu, India
A. Jayakrishnan*
Affiliation:
Biomaterials Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai600 036, Tamil Nadu, India
T. S. Sampath Kumar*
Affiliation:
Medical Materials Laboratory, Department of Metallurgical and Materials Engineering, Indian Institute of Technology Madras, Chennai600 036, Tamil Nadu, India
*
a)Address all correspondence to these authors. e-mail: jayakrishnan1953@gmail.com; jayakrishnana@rgcb.res.in
b)e-mail: tssk@iitm.ac.in
Get access

Abstract

In this study, a hybrid dual drug-loaded hydroxyapatite-oxidized dextran methacrylate core–shell nanocarrier was formulated and explored for combinatorial delivery of doxorubicin (DOX) and methotrexate (MTX) to bone cancer. The synthesized nanocarrier was well characterized by different techniques. In vitro drug release studies in both acidic (pH 5) and alkaline (pH 7.4) conditions showed sequential release of MTX followed by DOX in a sustained manner for 10 days. Biocompatibility and cytotoxicity studies performed using drug-loaded nanoparticles (NPs) on fibroblast L929 cells and osteosarcoma MG63 cells (OMG63) showed that the NPs were highly biocompatible and showed concentration-dependent toxicity. Gene expression studies in OMG-63 cells exhibited the upregulation of caspase-3 and BAX which confirmed the apoptosis induced by dual drug-loaded NPs. The nanocarrier is expected to be a potential bone void filling material, as well as a platform for sequential delivery of DOX and MTX for the treatment of bone cancer.

Information

Type
Article
Copyright
Copyright © Materials Research Society 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Supplementary material: File

Ram Prasad et al. Supplementary Materials

Ram Prasad et al. Supplementary Materials

Download Ram Prasad et al. Supplementary Materials(File)
File 3 MB